The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.

This technology includes the development of a stable cell line for the large-scale production of human Retinoschisin (RS1), a protein crucial for retinal health, which has potential therapeutic applications for X-Linked Retinoschisis (XLRS). XLRS is a genetic condition that leads to severe vision loss due to the malfunction of the RS1 protein. Current treatment options are limited, and this technology aims to provide a novel approach by producing RS1 in a human cell line, ensuring proper post-translational modifications and reducing immunogenicity. The stable cell line, derived from ARPE-19 cells, allows for consistent and high-yield production of RS1, which can be utilized for both therapeutic and research purposes. 

The technical solution involves the use of human ARPE-19 cells, which are known for their ability to produce and secrete proteins effectively. This cell line has been optimized to express RS1 and its variants, including mutant forms, under serum-free conditions, which is essential for therapeutic applications. The significance of this technology lies in its potential to improve patient outcomes for those suffering from XLRS by providing a reliable source of RS1 for treatment. 

The licensing opportunity for this technology is open for collaboration with industry partners interested in ocular therapeutics. The inventors are seeking partners who can assist in further development and commercialization of the RS1 protein and its delivery systems, including encapsulated cell-based therapies and nanoparticle formulations for targeted delivery to the retina.